Circulating tumor cell genomic evolution and hormone therapy outcomes in men with metastatic castration-resistant prostate cancer (mCRPC)

Men with circulating tumor cell (CTC) AR-V7 positive mCRPC have worse outcomes when treated with enzalutamide/abiraterone. However, most men lack CTC AR-V7 detection, and additional predictive-biomarkers are needed. We conducted a retrospective secondary analysis of the prospective PROPHECY trial (N...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mol Cancer Res
Hauptverfasser: Gupta, Santosh, Halabi, Susan, Kemeny, Gabor, Anand, Monika, Giannakakou, Paraskevi, Nanus, David M., George, Daniel J., Gregory, Simon G., Armstrong, Andrew J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2021
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8178231/
https://ncbi.nlm.nih.gov/pubmed/33771885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-20-0975
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge